Linda Klumpers and Mike Tagen from Verdient Science presented exciting research at the International Cannabinoid Research Society (ICRS) conference from June 30 – July 4, 2024 in Salamanca, Spain. This research was conducted in collaboration with Andriy Gorbenko, Jules Heuberger, and Geert Jan Groeneveld from Center for Human Drug Research in the Netherlands and Anebulo Pharmaceutics. The poster focused on an open-label part of a clinical trial evaluating selonabant as an antidote for high-dose acute cannabinoid intoxication (ACI) in healthy adults.

With rising emergency visits due to ACI, characterized by anxiety, panic, tachycardia, and psychosis mediated by delta-9-tetrahydrocannabinol (THC), the study explored selonabant’s potential to mitigate these effects. Prior parts A and B of the clinical trial showed that selonabant was safe and rapidly reversed THC-induced symptoms. Part C assessed selonabant’s ability to prevent symptoms from very high THC doses.

If you would like to send us your questions or comments, feel free to email us at [email protected].